Topical NVN1000 for the Treatment of External Genital and Perianal Warts
A Phase 2 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVN1000 in Subjects with External Genital Warts and Perianal Warts
Genital Warts|Perianal Warts
DRUG: NVN1000 8% Gel|DRUG: NVN1000 16%|DRUG: Vehicle|DRUG: NVN1000 24%
Efficacy: Complete Clearance of Baseline External Genital and Perianal Warts at or Before Week 12, Clearance of baseline external genital and perianal warts at or before Week 12 as determined by physical examination by the investigator., 12 weeks
Tolerability of Topical NVN1000 Gel as Determined by Scores on a 4 Point Grading Scale for Erythema, Edema, Erosions/Ulcers, and Itch, Comparison of scores for erythema, edema, erosions/ulcers, itch between active and vehicle treated subjects using a 4 point grading scale; on the tolerability scale, 0 = none and 3 = severe, indicating an increase in severity the higher the number assigned., Baseline, Week 2, Week 4, Week 8, Week 12|Safety as Determined by Changes in Laboratory Assessments, Safety population--Comparison of changes in methemoglobin levels between active and vehicle treated subjects. Methemoglobin levels were measured using a RAD-57 pulse co-oximeter. Values are expressed as a percentage of hemoglobin., Baseline, Week 2 and Week 12|Percentage of Subjects With Complete Clearance of Total EGW/PAW at or Before Week 12, The percentage of subjects with complete clearance of baseline and warts that emerge during treatment period as determined by physical examination by the investigator, 12 weeks|Percentage of Subjects With Complete or Partial Clearance of Baseline Warts at or Before Week 12, Percentage of subjects with complete or partial clearance of baseline warts as determined by physical examination by the investigator, 12 weeks
This is a phase 2, multi-center, randomized, double-blind, vehicle-controlled, ascending dose study to assess safety, tolerability and efficacy of a topical nitric oxide releasing compound in subjects with external genital and perianal warts. Eligible subjects will be treated with a topical gel (active or vehicle) for up to 12 weeks.